The developer of India’s leading indigenous coronavirus vaccine is already producing millions of doses of its yet-to-be-approved candidate, but the thought of supplying enough shots for half the country’s nearly 1.4 billion people can seem daunting at times. “It’s nightmarish,” said Suchitra Ella, joint managing director of Bharat Biotech International Ltd. “Sometimes I get goosebumps, sometimes I wake up early in the morning wondering where are we. What are we doing? How do we get there?” Bharat has already produced about 10 million doses of its Covaxin shot, ahead of an anticipated roll out by the middle of next year. It has a current annual capacity of 300 million shots and expects the first 100 million to be deployed by India, which has partly financed the development.
2,743,475.0
The developer of India’s leading indigenous coronavirus vaccine is already producing millions of doses of its yet-to-be-approved candidate, but the thought of supplying enough shots for half the country’s nearly 1.4 billion people can seem daunting at times.
“It’s nightmarish,” said Suchitra Ella, joint managing director of Bharat Biotech International Ltd. “Sometimes I get goosebumps, sometimes I wake up early in the morning wondering where are we. What are we doing? How do we get there?”
Bharat has already produced about 10 million doses of its Covaxin shot, ahead of an anticipated roll out by the middle of next year. It has a current annual capacity of 300 million shots and expects the first 100 million to be deployed by India, which has partly financed the development.
Sometimes I get goosebumps, says Bharat Biotech MD as firm preparing for Covaxin rollout
Suchitra Ella, Joint Managing Director, Bharat Biotech speaks to media where COVID19 Vaccine, Covaxin is being developed
3 min read
Chris Kay
Bharat has spent about $60 million to $70 million so far developing coronavirus vaccines
Share Via
Read Full Story
The developer of India’s leading indigenous coronavirus vaccine is already producing millions of doses of its yet-to-be-approved candidate, but the thought of supplying enough shots for half the country’s nearly 1.4 billion people can seem daunting at times.
“It’s nightmarish, said Suchitra Ella, joint managing director of Bharat Biotech International Ltd. “Sometimes I get goosebumps, sometimes I wake up early in the morning wondering where are we. What are we doing? How do we get there?
Press release content from Business Wire. The AP news staff was not involved in its creation.
Worldwide Meningococcal Vaccines Industry to 2025 - North America is Expected to Hold Largest Market Share - ResearchAndMarkets.com
December 18, 2020 GMT
DUBLIN (BUSINESS WIRE) Dec 18, 2020
The major factors for the growth of the meningococcal vaccines market include the increase in public-private partnerships to support the development of vaccines at low cost, and rising immunization programs and government initiatives.
ADVERTISEMENT
Key Market Trends
Polysaccharide Vaccine is expected to hold Largest Market Share over the Forecast Period
Internationally marketed meningococcal polysaccharide vaccines are bivalent (A and C), trivalent (A, C, and W-135) or tetravalent (A, C, Y, and W-135). The vaccines are purified, heat-stable, lyophilized capsular polysaccharides from meningococci of the respective serogroups. The vaccines have been helpful in curbing the exponential growth of the
India s coronavirus infections crossed the 10-million mark, despite a recent easing in the number of new cases as the country awaits several emergency vaccine approvals that may help tame the world s second-worst outbreak.
Some 25,152 new cases were added, according to the latest data from the federal Health Ministry released on Saturday, much lower than a peak of over 97,000 daily infections in mid-September. The number of deaths stood at 145,136, up 347 from Friday
India has said it expects to start rolling out its COVID-19 immunisation program as soon as a shot gets the green-light, but it has yet to approve a vaccine for early use authorization.